Blucora (NASDAQ:BCOR) Downgraded to “Sell” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Blucora (NASDAQ:BCOR) from a hold rating to a sell rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, “Blucora, Inc. provides technology-enabled financial solutions to consumers, small businesses and tax professionals. The company’s products and services consist of tax preparation and wealth management, through TaxAct and HD Vest. TaxAct provides digital tax preparation solution for individuals, business owners and tax professionals. HD Vest Financial Services (R) supports an independent network of tax professionals who provide comprehensive financial planning solutions. Blucora, Inc. is based in IRVING, Texas. “

BCOR has been the subject of a number of other reports. ValuEngine cut shares of Blucora from a buy rating to a hold rating in a research report on Saturday, May 18th. BidaskClub cut shares of Blucora from a sell rating to a strong sell rating in a research report on Thursday, August 8th. Finally, Barrington Research reiterated a buy rating and set a $36.00 price target on shares of Blucora in a research report on Monday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $38.00.

Shares of BCOR stock opened at $21.84 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.05 and a quick ratio of 2.43. The firm’s 50-day moving average is $28.41 and its two-hundred day moving average is $30.76. Blucora has a 12 month low of $21.81 and a 12 month high of $41.35. The company has a market capitalization of $1.17 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 0.73 and a beta of 0.58.

Blucora (NASDAQ:BCOR) last issued its earnings results on Wednesday, August 7th. The information services provider reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.12. Blucora had a net margin of 10.27% and a return on equity of 14.94%. The company had revenue of $193.70 million for the quarter, compared to the consensus estimate of $191.26 million. During the same period in the previous year, the firm earned $0.97 earnings per share. Blucora’s quarterly revenue was up 22.8% compared to the same quarter last year. Sell-side analysts forecast that Blucora will post 1.63 EPS for the current year.

In other Blucora news, Director H. Mcintyre Gardner sold 2,500 shares of Blucora stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $32.05, for a total transaction of $80,125.00. Following the completion of the sale, the director now directly owns 18,689 shares in the company, valued at $598,982.45. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John S. Clendening sold 10,000 shares of Blucora stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $29.23, for a total transaction of $292,300.00. Following the sale, the chief executive officer now owns 721,217 shares of the company’s stock, valued at $21,081,172.91. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,058 shares of company stock valued at $708,101. Company insiders own 3.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. NumerixS Investment Technologies Inc acquired a new position in shares of Blucora in the second quarter valued at approximately $67,000. Point72 Hong Kong Ltd acquired a new position in shares of Blucora in the second quarter valued at approximately $107,000. Quantamental Technologies LLC grew its holdings in shares of Blucora by 95.6% in the first quarter. Quantamental Technologies LLC now owns 3,720 shares of the information services provider’s stock valued at $124,000 after purchasing an additional 1,818 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Blucora by 112.2% in the first quarter. Bank of Montreal Can now owns 6,127 shares of the information services provider’s stock valued at $205,000 after purchasing an additional 3,239 shares in the last quarter. Finally, Sawtooth Solutions LLC acquired a new position in shares of Blucora in the first quarter valued at approximately $205,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About Blucora

Blucora, Inc provides technology-enabled financial solutions to consumers, small business owners, and tax professionals in the United States. The company operates through two segments, Wealth Management and Tax Preparation. The Wealth Management segment offers an integrated platform of brokerage, investment advisory, and insurance services to financial advisors.

Featured Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Blucora (BCOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Blucora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blucora and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Advanced Micro Devices, Inc.  CAO Sells $281,249.64 in Stock
Insider Selling: Advanced Micro Devices, Inc. CAO Sells $281,249.64 in Stock
Jack in the Box Inc.  CEO Sells $267,000.00 in Stock
Jack in the Box Inc. CEO Sells $267,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock   Insider Buys C$270,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock Insider Buys C$270,000.00 in Stock
Blucora  Downgraded to “Sell” at Zacks Investment Research
Blucora Downgraded to “Sell” at Zacks Investment Research
Assembly Biosciences  Cut to Hold at Zacks Investment Research
Assembly Biosciences Cut to Hold at Zacks Investment Research
Aptose Biosciences  Lowered to Hold at Zacks Investment Research
Aptose Biosciences Lowered to Hold at Zacks Investment Research


© 2006-2019 Ticker Report